<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40745313</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-0500</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>BMC research notes</Title><ISOAbbreviation>BMC Res Notes</ISOAbbreviation></Journal><ArticleTitle>Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial.</ArticleTitle><Pagination><StartPage>339</StartPage><MedlinePgn>339</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">339</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13104-025-07214-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effects of empagliflozin, sitagliptin, and metformin on the glycemic indices and cardiometabolic control of patients with type 2 diabetes mellitus (T2DM).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The significant changes in FBS from baseline to week 12 were -&#x2009;23.1, -16.15, and -&#x2009;15.25&#xa0;mg/dl in the empagliflozin, sitagliptin, and metformin arm, respectively. HbA1C decreased significantly from baseline to week 12 in the empagliflozin, sitagliptin, and metformin arm (-1.8, -1.35, -0.69%). The FBS and HbA1C changes were significant in the empagliflozin group compared to the metformin group (P&#x2009;=&#x2009;0.027, P&#x2009;=&#x2009;0.037, respectively). The weight changes were substantial in the empagliflozin group relative to the metformin group (-4.1 vs. -0.90&#xa0;kg; p&#x2009;=&#x2009;0.044). Compared with the metformin group, the adjusted mean difference in the empagliflozin group was -&#x2009;12.91&#xa0;mg/dl (95% CI: 31.82, 6; P&#x2009;=&#x2009;0.001) for triglyceride (TG) levels and 6.47&#xa0;mg/dl (95% CI: 2.93, 10.01; P&#x2009;=&#x2009;0.010) for high-density lipoprotein (HDL-c) levels. Moreover, empagliflozin led to reductions in SBP about -&#x2009;8.27&#xa0;mm Hg (95% CI: -13.31, -3.23; P&#x2009;=&#x2009;0.001) and in DBP about -&#x2009;13.37&#xa0;mm Hg (95% CI: -16.42, -10.32; P&#x2009;=&#x2009;0.001) compared with metformin.</AbstractText><AbstractText Label="TRAIL REGISTRATION NUMBER" NlmCategory="BACKGROUND">IRCT. ir (IRCT20191231045959N1).</AbstractText><AbstractText Label="TRAIL REGISTRATION DATE" NlmCategory="UNASSIGNED">2020-01-19.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mesri Alamdari</LastName><ForeName>Naimeh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barghaman</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roshanravan</LastName><ForeName>Neda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mobasseri</LastName><ForeName>Majid</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tutunchi</LastName><ForeName>Helda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baharami</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aliasgarzadeh</LastName><ForeName>Akbar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadra</LastName><ForeName>Vahideh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Sadra.vahideh@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Res Notes</MedlineTA><NlmUniqueID>101462768</NlmUniqueID><ISSNLinking>1756-0500</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>HDC1R2M35U</RegistryNumber><NameOfSubstance UI="C570240">empagliflozin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>TS63EW8X6F</RegistryNumber><NameOfSubstance UI="D000068900">Sitagliptin Phosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="Y">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="Y">Glucosides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068900" MajorTopicYN="Y">Sitagliptin Phosphate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Empagliflozin</Keyword><Keyword MajorTopicYN="N">Fasting plasma glucose</Keyword><Keyword MajorTopicYN="N">HbA1c</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Sitagliptin</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The experimental protocol was reviewed and approved by the Ethics Committee of Tabriz University of Medical Sciences (Ethical code: IR.TBZMED.REC.1398.850). Moreover, the study was performed by the Helsinki Declaration of 1964, and its later amendments; and all subjects provided informed consent to participate in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40745313</ArticleId><ArticleId IdType="pmc">PMC12315431</ArticleId><ArticleId IdType="doi">10.1186/s13104-025-07214-2</ArticleId><ArticleId IdType="pii">10.1186/s13104-025-07214-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atlas D. International diabetes federation. IDF Diabetes Atlas, 7th edn Brussels, Belgium: International Diabetes Federation. 2015;33(2).</Citation></Reference><Reference><Citation>Members ATF, Ryd&#xe9;n L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Eur Heart J. 2013;34(39):3035&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">23996285</ArticleId></ArticleIdList></Reference><Reference><Citation>Matin E, Ghaffari S, Garjani A, Roshanravan N, Matin S, Mesri Alamdari N, Safaie N. Oxidative stress and its association with ST resolution and clinical outcome measures in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. BMC Res Notes. 2020;13:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7656688</ArticleId><ArticleId IdType="pubmed">33176844</ArticleId></ArticleIdList></Reference><Reference><Citation>Roshanravan N, Tarighat-Esfanjani A, Alamdari NM, Kheirouri S, Mousavi R, Alizadeh M. The effects of zinc supplementation on inflammatory parameters in pregnant women with impaired glucose tolerance: a randomized placebo controlled clinical trial. Prog Nutr. 2018;20(1&#x2013;S):330e6.</Citation></Reference><Reference><Citation>Irandoost P, Mesri Alamdari N, Saidpour A, Shidfar F, Roshanravan N, Asghari Jafarabadi M, et al. The effects of Royal jelly and tocotrienol-rich fraction on impaired glycemic control and inflammation through Irisin in obese rats. J Food Biochem. 2020;44(12):e13493.</Citation><ArticleIdList><ArticleId IdType="pubmed">33020956</ArticleId></ArticleIdList></Reference><Reference><Citation>Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326926</ArticleId><ArticleId IdType="pubmed">16371403</ArticleId></ArticleIdList></Reference><Reference><Citation>Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American diabetes association and a scientific statement of the American college of cardiology foundation and the American heart association. Circulation. 2009;119(2):351&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19095622</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2015;38(1):140&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25538310</ArticleId></ArticleIdList></Reference><Reference><Citation>Irandoost P, Lotfi Yagin N, Namazi N, Keshtkar A, Farsi F, Mesri Alamdari N, Vafa M. The effect of capsaicinoids or capsinoids in red pepper on thermogenesis in healthy adults: A systematic review and meta-analysis. Phytother Res. 2021;35(3):1358&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">33063385</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na&#xef;ve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690334</ArticleId><ArticleId IdType="pubmed">26701110</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafipour M, Najafipour F, Ostadrahimi A, Ghavami M, Razaghi Z, Tutunchi H, Alamdari NM. The effects of empagliflozin in patients with type 1 diabetes: results of a 12-week, double-blind, randomized, placebo-controlled clinical trial. Health Promotion Perspect. 2024;14(4):380&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11873775</ArticleId><ArticleId IdType="pubmed">40041732</ArticleId></ArticleIdList></Reference><Reference><Citation>Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">23992601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to Metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2015;109(2):378&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">26059071</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng D-k, Xiao Q, Li F-q, Tang Y-z, Jia C-l. Tang X-w. Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. Biosci Rep. 2019;39(7):BSR20190980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6629947</ArticleId><ArticleId IdType="pubmed">31262972</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen F-S, Chiang J-H, Pan C-W, Lin BJ, Wei JC-C, Hsu C-C. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy. Diabetes Res Clin Pract. 2018;140:279&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">29654814</ArticleId></ArticleIdList></Reference><Reference><Citation>Talebi SS, Rezaie S, Hajmiri MS, Zamanirafe M, Ranjbar A, Moridi H et al. Comparison of the effects of empagliflozin and sitagliptin, as add-on to Metformin, on serum levels of Asprosin and metabolic parameters in patients with type 2 diabetes mellitus. Naunyn Schmiedebergs Arch Pharmacol. 2024:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">38900252</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakaraia H, Salem H, Mostafa M, Ali A, Rabea H. Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial. European Review for Medical &amp; Pharmacological Sciences. 2023;27(15).</Citation><ArticleIdList><ArticleId IdType="pubmed">37606137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">20067334</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003;42:1071&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">14531721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Inoue K, Saito D, Hamaguchi K, Kaneko K, Sumita T, et al. Effects of Dapagliflozin compared with sitagliptin and Metformin in drug-na&#xef;ve Japanese patients with type 2 diabetes: a 12-week, open-label, randomized, active-controlled trial. Diabetes Therapy. 2021;12:3201&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8586398</ArticleId><ArticleId IdType="pubmed">34709582</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">24622369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauber A, Mohamed A, Johnson F, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19388973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund A, Knop FK. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on Metformin and/or sulphonylurea. Curr Med Res Opin. 2012;28(5):731&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22462528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME&#x2122;). Cardiovasc Diabetol. 2014;13(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072621</ArticleId><ArticleId IdType="pubmed">24943000</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy. 2014:1380-.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166348</ArticleId><ArticleId IdType="pubmed">25246775</ArticleId></ArticleIdList></Reference><Reference><Citation>Halvorsen YD, Lock JP, Zhou W, Zhu F, Freeman MW. A 24-week, randomized, double&#x2010;blind, active&#x2010;controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to Metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metabolism. 2019;21(10):2248&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">31161692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hach T, Gerich J, Salsali A, Kim G, Hantel S, Woerle H, Broedl U. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetol Und Stoffwechsel. 2014;9(S 01):P142.</Citation></Reference><Reference><Citation>Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Can J Diabetes. 2013;37:S30.</Citation><ArticleIdList><ArticleId IdType="pubmed">25271206</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenl&#xf6;f K, Cefalu W, Kim KA, Alba M, Usiskin K, Tong C et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity and Metabolism. 2013;15(4):372&#x2013;&#x2009;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593184</ArticleId><ArticleId IdType="pubmed">23279307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945163</ArticleId><ArticleId IdType="pubmed">20566676</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Seman L, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle H. Efficacy and safety of Empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to Metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metabolism. 2013;15(12):1154&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23906374</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>